AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Group A streptococcal C5a peptidase is effective vaccine antigen.
2003 NOV 12 - (NewsRx.com & NewsRx.net) -- Group A streptococcal C5a peptidase is an effective vaccine antigen.
"The group A streptococcal C5a peptidase (SCPA) is a major surface virulence protein that facilitates the establishment of local infection by group A streptococci (GAS). We measured the human immune response to SCPA, using a standardized indirect enzyme-linked immunosorbent assay," investigators in the United States report.
"Paired acute and convalescent serum samples from children with GAS-associated pharyngitis were assayed, and a strong immune response to SCPA was demonstrated that was independent of the infecting M type and the age of the patient," said Anita Shet and colleagues at the University of Minnesota. "Western blot analysis of bacterial extracts revealed that all tested M types expressed SCPA. The immune response to SCPA correlated with the anti-streptolysin O and anti-DNase B responses."
"These data confirm the immunogenicity of SCPA in humans," concluded the researchers. "Previous knowledge of SPCA's role in virulence, its highly ...
- The Immune Response Corporation Evaluates a Second-Generation HIV Vaccine...
- Press release article from: Business Wire July 9, 2003 700+ words
...BUSINESS WIRE)--July 9, 2003 The Immune Response Corporation (Nasdaq:IMNR) and...HYBN.OB) today announced that The Immune Response Corporation is conducting preclinical...generation vaccine would be based on The Immune Response Corporation's whole-killed HIV...
- The Immune Response Corporation Initiates a Preclinical Development Program...
- Press release article from: PR Newswire November 3, 2003 700+ words
The Immune Response Corporation announced today that...BULLETIN BOARD: HYBN) to enhance the immune response to a vaccine antigen, with the...Phase II clinical trials by The Immune Response Corporation for the treatment of...
- Immune Response Stock Dips After Study.(securities information)(Brief...
- Magazine article from: San Diego Business Journal WEBB, MARION November 13, 2000 700+ words
Shares of Immune Response Corp. continued to hover in the...expectations. "The issue is, (Immune Response) had a high-risk drug and did...Remune. McCamant, however, said Immune Response has made a mistake by alienating...
- Immune Response Pins Hopes on Study Results.(Brief Article)
- Magazine article from: San Diego Business Journal WEBB, MARION September 10, 2001 700+ words
Officials at Immune Response Corp. said they will rely primarily...however, raised concerns whether Immune Response will be able to convince regulators...other data (to get approved)." Immune Response said Aug. 30 it will not pursue...
- The Immune Response Corporation Licenses Hybridon's 2nd-Generation CpG DNA...
- Press release article from: PR Newswire October 9, 2003 700+ words
The Immune Response Corporation and Hybridon, Inc...Phase II clinical trials by The Immune Response Corporation, plus AMPLIVAX, Hybridon...adjuvant designed to enhance the immune response to a vaccine antigen. The Immune...
- Schering-Plough and Immune Response in Agreement to Develop Hepatitis Gene...
- Press release article from: PR Newswire July 9, 1998 700+ words
...Corporation (NYSE: SGP) and The Immune Response Corporation (Nasdaq: IMNR) today...collaboration and option agreement to combine Immune Response's proprietary GeneDrug(TM) gene...gene therapy technology developed by Immune Response in conjunction with type-1 interferon...
- The Immune Response Corporation and NovaRx Corporation Announce Revision of...
- Press release article from: PR Newswire September 8, 2004 700+ words
The Immune Response Corporation , a biopharmaceutical...agreement to transfer all of The Immune Response Corporation's in-licensed development...addition, NovaRx agreed to pay The Immune Response Corporation the total sum of...
- The Immune Response Corporation Progress Report at the NYSSA 7th Annual Health...
- Press release article from: PR Newswire November 18, 2003 700+ words
The Immune Response Corporation announced today that...discussing the revitalization that The Immune Response Corporation has achieved during...2003 have been important for The Immune Response Corporation as we implemented our...
Source: HighBeam Research, Group A streptococcal C5a peptidase is effective vaccine antigen.